coadministered cagrilintide and semaglutide in adults with overweight or obesity Cagrilintide–Semaglutide Type 2 Diabetes nejm Semaglutide, a glucagon-like peptide-1
nejm Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential Cagrilintide & Semaglutide in Overweight Adults (REDEFINE 1) NEJM Med Journal Club In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Coadministered Cagrilintide and Semaglutide, in Adults with Overweight or Obesity. June 22,, 2025. DOI: 10.1056 NEJMoa2502081, CagrilintideSemaglutide in Adults with, Overweight or Obesity and Type 2 Combined GLP 1 amylin analog bests monotherapy for HbA1c drop, weight loss in diabetes
Pay in 4 interest-free payments of $5.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8


